(Reuters) – Roivant Sciences Ltd is attracting interest from large pharmaceutical companies for its inflammatory bowel disease drug, Bloomberg News reported on Thursday, citing people familiar with the matter.
While deliberations have focused on the treatment, which could be worth more than $7 billion, it’s possible the entire company could be sold as well, the report said.
Roivant said it had no comment at the moment on the matter when contacted by Reuters.
(Reporting by Khushi Mandowara in Bengaluru; Editing by Sriraj Kalluvila)
